Brooks Laboratories Limited (BOM:533543)
India · Delayed Price · Currency is INR 75.89
-1.61 (-2.08%)
At close: Feb 13, 2026
Brooks Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Revenue | 888.46 | 825.57 | 794.86 | 632.05 | 911.85 | 772.47 |
Revenue Growth (YoY) | 15.44% | 3.86% | 25.76% | -30.69% | 18.04% | 10.85% |
Cost of Revenue | 549.62 | 546.21 | 569.73 | 524.09 | 639.79 | 485.69 |
Gross Profit | 338.84 | 279.36 | 225.13 | 107.95 | 272.06 | 286.78 |
Selling, General & Admin | 150.07 | 132.73 | 107.94 | 176.94 | 194.68 | 146.43 |
Other Operating Expenses | 106.12 | 93.82 | 78.14 | 194.77 | 217.67 | 134.57 |
Operating Expenses | 271.83 | 242.56 | 203.82 | 441.97 | 485.86 | 352.44 |
Operating Income | 67.01 | 36.81 | 21.32 | -334.02 | -213.8 | -65.66 |
Interest Expense | -8.29 | -8.5 | -7.25 | -19.54 | -28.31 | -30.98 |
Interest & Investment Income | 2.95 | 2.95 | 1.07 | 1.27 | 0.91 | 1.85 |
Earnings From Equity Investments | 150.75 | -129.84 | -211.21 | -33.1 | - | -0.08 |
Currency Exchange Gain (Loss) | 1.4 | 1.4 | 1.53 | -0.43 | 2.22 | - |
Other Non Operating Income (Expenses) | 2.91 | -1.78 | -1.2 | -1.53 | -1.31 | 5.51 |
EBT Excluding Unusual Items | 216.72 | -98.97 | -195.74 | -387.35 | -240.29 | -89.37 |
Gain (Loss) on Sale of Investments | 0.08 | 0.08 | 0.08 | 0.08 | - | - |
Gain (Loss) on Sale of Assets | 0.1 | 0.1 | - | - | 1.31 | -0.56 |
Other Unusual Items | 0.88 | 0.88 | - | 3.57 | - | - |
Pretax Income | 217.78 | -97.92 | -195.66 | -383.7 | -238.98 | -89.93 |
Income Tax Expense | 1.75 | 1.75 | 0.26 | -73.24 | -45.85 | 103.82 |
Earnings From Continuing Operations | 216.03 | -99.67 | -195.92 | -310.46 | -193.13 | -193.76 |
Minority Interest in Earnings | - | - | - | 101.54 | 80.23 | - |
Net Income | 216.03 | -99.67 | -195.92 | -208.92 | -112.9 | -193.76 |
Net Income to Common | 216.03 | -99.67 | -195.92 | -208.92 | -112.9 | -193.76 |
Shares Outstanding (Basic) | 29 | 27 | 26 | 25 | 25 | 25 |
Shares Outstanding (Diluted) | 29 | 27 | 26 | 25 | 25 | 25 |
Shares Change (YoY) | 11.78% | 4.59% | 3.70% | - | - | 40.27% |
EPS (Basic) | 7.40 | -3.72 | -7.65 | -8.46 | -4.57 | -7.84 |
EPS (Diluted) | 7.40 | -3.72 | -7.65 | -8.46 | -4.57 | -7.84 |
Free Cash Flow | - | 17.04 | -102.4 | -149.58 | -650.53 | -11.55 |
Free Cash Flow Per Share | - | 0.64 | -4.00 | -6.05 | -26.33 | -0.47 |
Gross Margin | 38.14% | 33.84% | 28.32% | 17.08% | 29.84% | 37.13% |
Operating Margin | 7.54% | 4.46% | 2.68% | -52.85% | -23.45% | -8.50% |
Profit Margin | 24.32% | -12.07% | -24.65% | -33.05% | -12.38% | -25.08% |
Free Cash Flow Margin | - | 2.06% | -12.88% | -23.67% | -71.34% | -1.49% |
EBITDA | 78.02 | 49.45 | 36.15 | -267.44 | -143.15 | 3.15 |
EBITDA Margin | 8.78% | 5.99% | 4.55% | -42.31% | -15.70% | 0.41% |
D&A For EBITDA | 11.01 | 12.65 | 14.83 | 66.58 | 70.65 | 68.82 |
EBIT | 67.01 | 36.81 | 21.32 | -334.02 | -213.8 | -65.66 |
EBIT Margin | 7.54% | 4.46% | 2.68% | -52.85% | -23.45% | -8.50% |
Effective Tax Rate | 0.80% | - | - | - | - | - |
Revenue as Reported | 901.98 | 834.4 | 804.04 | 634.16 | 919.86 | 779.82 |
Advertising Expenses | - | 2.97 | 2.45 | 3.43 | 2.6 | 2.57 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.